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Received 12 November 2006; received in revised form 28 January 2007; accepted 29 January 2007; Available online 19 April 2007SummaryAccurate preoperative staging and restaging of mediastinal lymph nodes in patients with non-small cell lung cancer (NSCLC) is of paramount
importance. It will guide choices of treatment and determine prognosis and outcome. Over the last years, different techniques have become
available. They vary in accuracy and procedure-related morbidity. The Council of the ESTS initiated a workshop on preoperative mediastinal
lymph node staging. This resulted in guidelines for primary staging and restaging. For primary staging, mediastinoscopy remains the gold standard
for the superior mediastinal lymph nodes. Invasive procedures can be omitted in patients with peripheral tumors and negative mediastinal
positron emission tomography (PET) images. However, in case of central tumors, PET hilar N1 disease, low fluorodeoxyglucose uptake of the
primary tumor and LNs  16 mm on CT scan, invasive staging remains indicated. PET positive mediastinal findings should always be cyto-
histologically confirmed. Transbronchial needle aspiration (TBNA), ultrasound-guided bronchoscopy with fine needle aspiration (EBUS-FNA) and
endoscopic esophageal ultrasound-guided fine needle aspiration (EUS-FNA) are new techniques that provide cyto-histological diagnosis and are
minimally invasive. Their specificity is high but the negative predictive value is low. Because of this, if they yield negative results, an invasive
surgical technique is indicated. However, if fine needle aspiration is positive, this result may be valid as proof for N2 or N3 disease. For restaging,
invasive techniques providing cyto-histological information are advisable despite the encouraging results supported with the use of PET/CT
imaging. Both endoscopic techniques and surgical procedures are available. If they yield a positive result, non-surgical treatment is indicated in
most patients.
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Correct staging of patients with non-small cell lung cancer
(NSCLC) provides accurate information on the extent of
disease and guides the choice of treatment. It is also
fundamental for estimating prognosis and for comparison of
studies. When there are no distant metastases, mediastinal
lymph node (LN) involvement is the most important
prognostic factor in patients with NSCLC and influences
therapeutic strategies. Patients with tumors in clinical stage
III are a heterogeneous group in whom the extent of LN* Corresponding author. Address: Department of Thoracic Surgery, Univer-
sity Hospitals Leuven, Herestraat 49, B 3000 Leuven, Belgium.
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doi:10.1016/j.ejcts.2007.01.075involvement before and after induction therapy determines
outcome.
Patients with preoperatively diagnosed involved mediast-
inal LNs have a dismal outcome when treated with surgery or
radiotherapy alone. In order to improve the outcome in these
patients, the concept of multimodality treatment has been
introduced. In the subgroup of patients with IIIA-N2 disease
induction chemotherapy, combined with either surgery and/
or radiotherapy has proved to be effective (Table 1).
Even in the setting of surgical combined modality,
complete resection is an essential element in the potential
of cure. Therefore, an important aim of staging procedures in
these patients will be to guide the multidisciplinary decision
on whether the patient is a candidate for resection, based on
baseline and postinduction assessment. If complete resection
is considered unlikely, a non-surgical multimodality approachSurgery. Published by Elsevier B.V. All rights reserved.
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Table 1
Influence of downstaging of mediastinal lymph nodes after induction treatment and surgical resection for mediastinoscopy proven N2 disease
Author Year No. of patients Surgery (%) Complete resection (%) Results in surgery group
Downstaging
(%) a
Survival
overall (%)
Survival
downstaging (%)
Survival
pN2 (%)
Bueno et al. [39] 2000 NRb NR (103) NR 28 18 36 9
Betticher et al. [40] 2003 90 87 55 63 NR 61 (3 years) 11 (3 years)
Lorent et al. [41] 2004 131 57 53 45 35 44 14
Intergroup trial 0139 [24] 2005 202 81 71 41 27 41 24
EORTC 08941 Trial [25] 2005 167 92 50c 42 16 29 7
% Complete resection: number of complete resection on total number of included patients.
NR: not reported.
Study by Betticher et al. [40] and Lorent et al. [41] give results of induction chemotherapy for N2 disease.
Intergroup trial compares CT/RT versus CT/RT + surgery for patients with N2 disease.
EORTC trial compares RT versus Surgery in responding patients after induction chemotherapy for N2 disease.
a Downstaging: disappearance of tumor from mediastinal nodes.
b Denominator is not in manuscript. Only data on complete resections after induction chemotherapy.
c Strict criteria were used for complete resection (highest mediastinal lymph node had to be negative).is preferred. Therefore, a precise and accurate preoperative
and postinduction LN evaluation is mandatory.
After a first successful workshop on intra-operative LN
staging [1], the ESTS Council initiated a second workshop on
preoperative mediastinal LN staging.
The working group had three sessions in Zu¨rich. Initial
findings were presented and discussed at the postgraduate
meeting of the EACTS—ESTS meeting in Barcelona (Septem-
ber 2005). The final paper was put on the website for
discussion by all ESTS members. Their remarks were
discussed and included in the final manuscript.
It is evident that both in primary staging and restaging, not
every technique is available in every centre. Therefore,
staging and restaging techniques can differ between
different countries and centres.2. Primary mediastinal LN staging
2.1. Imaging techniques
2.1.1. Chest CT scan
Computer tomography (CT) still plays a central role in lung
cancer imaging. For the N-factor, modern contrast CT is very
accurate in detecting LN enlargement, but the clinical
relevance of LN enlargement for staging is poor because small
nodes may contain metastases in up to 20% [2] and largeTable 2
Performance of different locoregional staging techniques (adapted from
Toloza et al. [3])
Sensitivity
(%)
Specificity
(%)
NPV
(%)
PPV
(%)
Prevalence
(%)
CT 57 82 83 56 28
PET 84 89 93 79 32
Blind TBNA 76 96 71 100 70
EUS-FNA 88 91 77 98 69
Mediastinoscopy 81 100 91 100 37
NPV: negative predictive value; PPV: positive predictive value; TBNA: trans-
bronchial needle aspiration; EUS-FNA: endoscopic esophageal ultrasound-
guided fine needle aspiration; prevalence: proportion of patients with meta-
static mediastinal nodes in the study cohorts.nodes may be benign. A diameter larger than 1 cm in the
short axis is generally considered as the standard criterion for
a suspicious LN. This definition reduces the false negative
interpretations, which is of importance regarding the
possible inclusion in an induction protocol. In a review,
pooled data yielded a sensitivity of 57%, a specificity of 82%, a
positive predictive value of 56% and a negative predictive
value (NPV) of 83%, with a marked heterogeneity across
individual studies ([3], Table 2). In these guidelines, a LNwith
a diameter smaller than 1 cm in the short axis is defined as
N0.
This performance is insufficient for clinical decision
making, and in many instances it is inappropriate to rely
solely on CT scan for N-staging, but it can be of help in
selecting the most appropriate procedure for tissue sampling
of suspected LNs. Cervical mediastinoscopy is recommended
in patients with resectable NSCLC and N0 disease on CT scan
except from those with a T1 squamous cell tumor with N0
disease on CT scan [4].
2.1.2. PET scan
Non-invasive lung cancer staging was substantially
improved by the use of positron emission tomography with
18F-fluoro-2-deoxy-D- glucose (FDG-PET). A large number of
accuracy studies and meta-analyses have demonstrated that
PET is superior to CT for mediastinal LN staging in potentially
operable NSCLC [5].
Sensitivities and negative predictive values (NPVs) were
comparable for PET compared with mediastinoscopy
(Table 2). However, the positive predictive value and the
specificity of FDG PET scan are lower than those of
mediastinoscopy due to the fact that FDG is also taken up
by inflammatory processes.
Due to the high NPV of PET scan, invasive staging
procedures like mediastinoscopy can generally be omitted
in patients with clinical stage I NSCLC with negative
mediastinal PET images. This implementation should be
dealt with caution in case of patients with central tumors,
central hilar N1 disease on CT scan, bronchio-alveolar cell
carcinoma or in all situations with low FDG uptake in the
primary tumor and mediastinal PET negative LNs 16 mm on
CT scan [6—8].
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Fig. 1. Regional lymph node stations for lung cancer staging (fromMountain CF,
Dresler CM. Chest 1997;11:1718—1723 [12] with permission).In a recentmeta-analysis [9], a post-test probability for N2
disease of 21% was found in patients with PET negative nodes
16 mm.
The implementation of PETas shown in algorithm in Fig. 5
reduced the number of mediastinoscopies by 65% [6].
Moreover, after a negative conventional staging, unknown
metastasis can be found on PET in 5—29% of the patients.
We realize that some occasional patients with a false
negative mediastinal PET will proceed straight to thoracot-
omy. When PET scan is implemented as discussed above, the
rate of unforeseen N2 disease is expected to be below 10%
[8,9]. In these cases however, minimal N2 is usually found and
a reasonable prognosis can be expected after surgical
resection.
The positive predictive value of PET scan is only 79%. In
case of positive mediastinal PET, tissue confirmation is still
needed to confirm LN metastasis. The main drawback of PET
is the poor quality of its anatomic information. Tracing focal
abnormalities to specific LNs can be difficult or even
impossible with use of PET alone, specially in the exact
localisation of a single focal abnormality between level 4R
(N2) and level 10R (N1). Recently, integrated PET—CT
scanners have been introduced [10]. The great advantage
of this technique consists of the precise anatomical
correlation of the radionuclide uptake, an identical position-
ing of the patient, no time interval for data acquisition and no
additional work for collecting data. The available studies
show an increased diagnostic accuracy of integrated PET—CT
with respect to PET scan alone [11].
2.2. Invasive techniques
2.2.1. Invasive surgical staging
2.2.1.1. Mediastinoscopy. Mediastinoscopy remains the gold
standard for invasive staging of patients with potentially
operable lung cancer. Different forms of mediastinoscopy
have been described. Cervical mediastinoscopy is the most
commonly used. It is a surgical open biopsy technique under
general anesthesia.
According to the LN map proposed by Mountain and
Dresler ([12]; Fig. 1), the following LN stations can be
evaluated by cervical mediastinoscopy: the highest med-
iastinal LN station (level 1), the right and left superior
paratracheal LN stations (level 2 right, level 2 left), the right
and left inferior paratracheal LN stations (level 4 right, level
4 left) and the subcarinal LN station (level 7).
There is no internationally accepted recommendation on
how many LN stations should be examined at cervical
mediastinoscopy. There are no data indicating that more
systematic sampling at mediastinoscopy makes a difference,
but extrapolation from data on occasional and systematic
sampling at thoracotomy suggests that this may be important
[1]. The opinions vary among working groups and authors
around the world:- The American Thoracic Society stated that all reachable
nodal stations should be explored. According to the ATS
nodal map, these include the right and left superior
paratracheal stations (levels 2R and 2L), right and left
inferior paratracheal (levels 4R and 4L), right and lefttracheobronchial (levels 10R and 10L) and subcarinal
(level 7) stations. The ATS also recommended performing
left parasternal mediastinotomy to explore the subaortic
(level 5) and anterior mediastinal (level 6) stations in
patients with left lung tumors.- For Detterbeck et al. [13], the ideal exploration would
include at least one node from the right and left, superior
and inferior paratracheal and subcarinal stations, unless
more nodes are present.- Smulders et al. [14] assessed the quality of mediastinos-
copies performed both in teaching and non-teaching
hospitals. They found a large variability in the performance
of mediastinoscopy for initial staging for NSCLC. In only 40%
of mediastinoscopies performed for NSCLC three or more
LN levels were sampled [14]. They suggest that the
minimally acceptable exploration includes biopsy of nodes
from the inferior paratracheal stations on both sides, and
from the subcarinal station, with the addition of at least
one contralateral LN. They consider that the inclusion of
the superior paratracheal nodes on both sides could not be
required in standard clinical practice, because they might
be difficult to reach.
In summary, there seem to be two standards for mediastino-
scopy described according to the latest LN map of Mountain—
Dresler [12]:- Ideally, the following nodal stations should be explored and
their LNs biopsied:
- right and left superior paratracheal nodes (level 2R and
level 2L),
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level 4L),
- subcarinal (level 7).But a lesser standard could be accepted for routine clinical-
practice:
- right and left inferior paratracheal nodes (level 4R and
level 4L),
- subcarinal nodes (level 7).The ESTS working group recommends to systematically
explore and biopsy always the right and left lower
paratracheal nodes and the subcarinal nodes. Additionally,
if present, the upper paratracheal LNs should be sampled and
biopsied.
An advantage of mediastinoscopy over fine needle
aspiration is that a more complete mediastinal mapping
can be performed including contralateral LN stations. This
might be important in the differentiation and treatment
planning of patients with single and multi-level N2 disease. In
a recent review, the sensitivity of cervical mediastinoscopy
varied between 72% and 89%, with an average of 81% with a
NPV of 91% [15]. The prevalence of N2 disease in these series
was 37% which is the expected prevalence of N2 disease in
patients with potentially resectable NSCLC. The results of
the suboptimal sensitivity can partly be explained by the fact
that some LN stations (levels 5, 6, posterior part of level 7 and
levels 8 and 9) are not accessible by cervical mediastino-
scopy.
More recently, mediastinoscopy is performed by the use of
a videomediastinoscope ([16] Fig. 2). This definitely improves
visualisation of the operative field and may lead to a higher
accuracy in staging and a better standardisation of the
technique [17,18]. The learning curve of video-assistedFig. 2. Cervical videomediastinoscopy.mediastinoscopy is short compared to conventional medias-
tinoscopy [19].
Some groups have developed techniques for mediastinal
lymphadenectomy through a cervicotomy approach (VAMLA,
video-assisted mediastinoscopic lymphadenectomy [20]—
TEMLA, transcervical extended mediastinal lymphadenect-
omy [21]). The aim of both techniques is to perform a
complete bilateral lymphadenectomy of the mediastinum
including stations 2,4,7 and 8 (VAMLA) and stations 1,2,3A,
3P, 4,5,6,7 and 8 (TEMLA) for staging purposes. The potential
advantage of these two lymphadenectomy techniques is that
by removing the nodes, the false negative results caused by
micrometastases can be reduced. The results of these two
studies with a limited number of patients show a very high
accuracy and NPV (between 0.95 and 1). However, the value
of these techniques needs to be further explored before they
can be implemented in routine practise.
Tumors of the left upper lobe may metastasize to the
subaortic (level 5) and anterior mediastinal (level 6) nodes.
These nodal stations cannot be reached by cervical medias-
tinoscopy. Left parasternal mediastinotomy, extended cervi-
cal mediastinoscopy, and left thoracoscopy allow exploration
and biopsy of these nodal stations and should be used in
combination with cervical mediastinoscopy to stage these LN
stations as indicated. Thoracoscopy can also be used for LN
levels which are not accessible by routine mediastinoscopy
(levels 8 and 9). These lymph node levels can be biopsied with
esophageal ultrasound-guided fine needle aspiration (EUS/
FNA).
2.2.2. Invasive non-surgical staging
Endoscopic techniques are minimally invasive
approaches that provide histological or cytological con-
firmation of nodal tumor involvement. Transbronchial
needle aspiration (TBNA) has been shown to be safe and
useful in patients with enlarged mediastinal LNs. However,
this technique has a moderate yield, is a ‘blind’ technique,
operator dependent, and the results depend on the size of
the LN. In a recent overview, a sensitivity of 76% and a false
negative rate of 29% were reported for conventional TBNA in
clinical N2 disease (Table 2). This high false negative rate
compromises the use of conventional TBNA for routine
mediastinal LN staging, however it can be used as a
preliminary diagnostic test complemented in negative cases
with surgical staging. The accuracy can be improved by
guidance with endoscopic ultrasonography (EBUS-TBNA).
Additionally, the hilar (station 10) and intrapulmonary nodal
stations can be biopsied with TBNA. EBUS-TBNA and cervical
mediastinoscopy can provide histology of the superior
mediastinal LNs (levels 2 and 4, right and left) and the
subcarinal LNs (level 7) (Fig. 3).
In a recent meta-analysis including 13 studies in which all
TBNA results were confirmed by surgical biopsies, it was
shown that the sensitivity of TBNA critically depends on the
prevalence of mediastinal LNmetastases. In populations with
a lower prevalence of mediastinal metastases, the sensitivity
of TBNA is much lower than reported in recent lung cancer
guidelines [22].
Esophageal ultrasound-guided fine needle aspiration (EUS-
FNA) is mainly suitable for the assessment of LNs in the
posterior part of levels 4L, 5 and 7 and in the inferior
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Fig. 4. The proposed algorithm to follow for primary mediastinal staging when
PET scan is not available.
Fig. 3. Illustration of nodal levels which can be reached by cervical medias-
tinoscopy and EBUS-TBNA versus nodal levels which are accessible by EUS-FNA.mediastinum at levels 8 and 9 as described on the Mountain—
Dresler map (Fig. 3).
A review of the literature reported a pooled sensitivity of
88%, a specificity of 91%, a positive predictive value of 98% and
a NPV of 77%. A recent study in 100 patients with potentially
operable NSCLC who were scheduled for mediastinoscopy
showed that the combination ofmediastinoscopy and EUS-FNA
significantly improved sensitivity and NPV [23].
However, most of the accuracy studies on invasive non-
surgical staging were performed in patients with a high
suspicion of N2—N3 disease. When the prevalence of involved
mediastinal LNs is high as mentioned above, an improved
sensitivity is to be expected which does not reflect the
accuracy in patients with normal sized LNs. It is generally
accepted that endoscopic techniques (both EBUS and EUS/
FNA) are suitable to provide histological proof of suspicious
mediastinal LNs but cannot be used to excludemediastinal LN
disease because of the low NPV.
Transthoracic needle aspiration (TTNA) is performed with
CTor, less often, with fluoroscopic guidance. Generally, TTNA
is used in patients with enlarged or bulky mediastinal LNs.
Almost all mediastinal nodal stations are accessible with this
technique; stations 1, 2, 4, 5 and 6 are accessible using
anterior parasternal approach and stations 4, 7, 8 and 9 are
approached with the posterior paraspinal approach.
2.3. Guidelines for baseline mediastinal LN staging
- Chest CT is still the basic imaging modality in lung cancer.
However, CT scan of the chest is not accurate enough for
mediastinal LN staging. When only CT scan is available,
invasive staging is advised in every patient except for a
T1squamous cell tumor with LNs < 1 cm on CT scan.
Invasive staging can be omitted in patients with stage I
NSCLC and negative mediastinal PET images. However, in
case of central tumors, PET hilar N1 disease, low FDG
uptake of the primary tumor and LNs  16 mm on CT,
invasive staging remains indicated.- PET positive mediastinal findings should be histologically or
cytologically confirmed.- TFig. 5. The proposed algorithm to follow for primary mediastinal staging when
PET or PET/CT scan is available.ransbronchial needle aspiration, ultrasound-guided
bronchoscopy (EBUS-FNA), esophagoscopy (EUS-FNA) and
transthoracic needle aspiration (TTNA) are new techniques
that provide cyto-histological diagnosis and are minimally
invasive techniques. They can be complementary tosurgical invasive staging techniques. Their specificity is
high, but their NPV is low. For this reason an invasive
surgical technique is indicated if they yield negative
results. However, if fine needle aspiration is positive, this
result may be valid as proof of N2 or N3 disease.- Cervical mediastinoscopy provides the advantage that a
more complete mapping of mediastinal LNs can be
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4R, 2L 4L and 7) should be explored and biopsied. At least
one ipsilateral, one contralateral and the subcarinal LNs
should be biopsied.- The proposed algorithm for primary mediastinal staging
when no PET scan is available is detailed in Fig. 4. Fig. 5
shows the algorithm when PETor PET/CTscan is available.3. Mediastinal lymph node restaging after induction
therapy
Recent studies suggest that mainly patients with initial
stage IIIA or IIIB and mediastinal downstaging will benefit
from surgical resection (Table 1). However, postoperative
morbidity and mortality may be higher after resection
following induction therapy compared with resection without
induction treatment. As a consequence, mediastinal resta-
ging after induction therapy is required to aid proper
selection of patients likely to benefit from surgical resection.
An important question remains whether a better local
control and survival are obtained by induction therapy and
surgery compared to standard chemoradiotherapy. Recently,
the results of two large randomized trials became available.
In the Intergroup, 0139 trial patients with proven stage IIIA-
N2 NSCLC were randomized between a full course of
chemoradiotherapy and induction chemoradiotherapy + sur-
gery [24]. There was no significant difference in overall
survival between both arms. However, there was a difference
in progression-free survival favoring the surgical arm, and
patients downstaged to ypN0 disease had a far better
prognosis. The rate of locoregional recurrence was also
significantly less in the surgical arm.
In the EORTC 08941 phase III trial, patients with
unresectable clinical stage IIIA-N2 disease were randomized
between surgery and radiotherapy after a response to
induction chemotherapy [25]. There was no difference in
overall and progression-free survival between both arms. The
data of these two trials are however only available in abstract
form which impairs a precise analysis and a fair interpreta-
tion of the results.
The mediastinum can be principally restaged by the same
techniques as applied in primary staging.
3.1. Imaging techniques
In primary staging, CT scan has proved to have a low
accuracy. It is not surprising that the accuracy of CT scan in
restaging the mediastinum is also low. In two studies, theble 3
agnostic accuracy of re-mediastinoscopy after induction treatment for mediastino
thor Year No. Sensitivity (%)
teu-Navarro et al. [26] 2000 24 70
n Schil et al. [33] 2002 27 73
z et al. [35] 2002 15 NR
amatis et al. [34] 2005 165 78
Leyn et al. [11] 2006 30 29
: not reported.
V: negative predictive value.sensitivity of CT scan for mediastinal restaging was 41% and
59%, specificity 75% and 62% and accuracy 58% and 60%,
respectively [11,26].
For mediastinal restaging after induction chemotherapy,
PET scan is more accurate than CT but is clearly not as
accurate as in untreated patients [27—31]. In most studies,
the sensitivity is reported to be 50—60% with a good
specificity of 85—90%. So, in a high proportion of patients,
PET scan is false negative regarding mediastinal nodal
involvement after induction therapy. The reason for this
poor sensitivity is not clear. A very small mass of residual
tumor, such as post-treatment microscopic foci surrounded
by fibrosis may be more difficult to detect. Changes in the
microenvironment of the tumor such as altered perfusion due
to postchemotherapy changes, may also impair presentation
of FDG to the metastatic LNs.
In a prospective study [11], the use of PET—CT fusion
images significantly increased the accuracy through better
localisation of focal FDG update in mediastinal LNs or other
vascular—mediastinal structures. This study showed that
PET—CT had a high positive predictive value (93%) in
detecting residual mediastinal disease. Moreover, complete
resectability was low (57%) in patients with persistent
mediastinal findings on PET—CT. However, in another study
[32] the PPV was only 75% and the authors concluded that
persistent positive mediastinal findings on PET should be
histopathologically proven.
It seems that the comparison of SUV max values before
and after induction chemotherapy allow prediction of
histopathologic response in the primary tumor and mediast-
inal LNs and have prognostic value [32].
3.2. Invasive techniques
3.2.1. Invasive surgical staging
Repeat mediastinoscopy, although technically more
difficult than the first procedure, offers the advantage of
providing histological evidence of response after induction
therapy.
Only a few centres have reported their experience with
repeat mediastinoscopy (Table 3). Mateu-Navarro et al. [26]
reported on 24 patients who underwent re-mediastinoscopy
after induction chemotherapy for mediastinoscopy proven N2
disease. The sensitivity to detect residual mediastinal
disease was 70%. Van Schil et al. [33] reported very similar
results in 27 patients with no mortality and only minimal
morbidity. The largest experience of repeat mediastinosco-
pies after induction therapy to date was recently reported by
Stamatis et al. [34]. In a study from the Netherlands, re-scopy proven N2 disease
NPV (%) Findings at initial mediastinoscopy
No. of levels biopsied Multilevel disease (%)
NR NR 12
75 NR 37
NR NR NR
86 4.2 NR
52 3.8 33
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tinoscopy was inadequate or incomplete in 6 patients and the
authors concluded that the examination was not that
effective [35].
A prospective study evaluated the accuracy of re-
mediastinoscopy and PET—CT in restaging the mediastinum
after videomediastinoscopy proven N2 disease in 30 patients
[11]. The authors concluded that, after a thoroughly
performed initial videomediastinoscopy, repeat videome-
diastinoscopy was technically feasible but inaccurate due to
severe adhesions and fibrosis. The sensitivity to detect
residual positive mediastinal LNs was only 29%, with an
accuracy of 60%. It seems that the degree of adhesions and
mediastinal fibrosis is mainly secondary to preinduction
mediastinoscopy rather than to induction treatment itself
[36]. In a study comparing accuracy and safety of videome-
diastinoscopy in patients without pretreatment and in
patients after induction therapy but without preinduction
mediastinoscopy, sensitivity, specificity and accuracy were
comparable without additional morbidity [18].
A study investigated the role of VATS in restaging of the
mediastinum after induction therapy for N2 disease in 70
patients [37]. In 17 patients, the VATS procedure was not
successful due to fibrosis. A sensitivity of 75%, a specificity of
100% and a NPV of 75.8% were reported. However, the value
of this technique needs to be further explored before it can
be implemented in routine practise.
3.2.2. Invasive non-surgical techniques
An alternative, less invasive test to restage the medias-
tinum after induction chemotherapy is transbronchial or
transesophageal ultrasound-guided biopsy. A study from the
Netherlands reported results in 19 patients with proven N2
disease which were restaged by EUS after induction
chemotherapy [38]. Diagnostic accuracy in this study was
83%.
Restaging of the mediastinum after induction treatment
for N2 disease is of paramount importance. CT is by far not
accurate enough for restaging. Re-mediastinoscopy has
proven to be feasible but due to adhesions and fibrosis,
the intervention is technically challenging and sensitivity and
accuracy are lower than after a first mediastinoscopy. The
accuracy of PET in mediastinal restaging is far from optimal,
mainly due to its low sensitivity. Fusion images with PET—CT
are reported to improve the results. Less invasive techni-
ques, such as EUS-FNA seem to yield similar results as VATS
and re-mediastinoscopy. An alternative approach is the use of
EBUS or EUS-FNA for primary staging and reserve mediastino-
scopy for mediastinal restaging after induction therapy.
In order to obtain the most precise restaging, an
integration of these procedures is highly recommended,
especially in the context of clinical trials and to maintain the
morbidity as low as possible.
3.3. Guidelines for restaging
Restaging of the mediastinum after induction therapy is
necessary.
At the present time, neither CT, PET or PET—CT are
accurate enough to make final further therapeutic decisions
based on their results.An invasive technique providing cyto-histological informa-
tion is recommended. For restaging, endoscopic techniques
or surgical invasive techniques can be used. If they yield a
positive result, non-surgical treatment seems to be indicated
in most of the patients. The choice may be dependent on the
availability of the technique and expertise of the centre.
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